Table 2. Side effects of R115777... | American Society of Hematology

Table 2.

Side effects of R115777

Toxicity	No. patients (%)	No. with dose-limiting toxicity (%)^*
Myelosuppression	19 (91)	1 (5)
Fatigue	11 (52)	3 (14)
Rash	7 (33)	0
Nausea	7 (33)	0
Bilirubin increase	5 (24)	0
Constipation	4 (19)	0
Diarrhea	3 (14)	0
Bone pain	3 (14)	0
Myalgia	2 (10)	1 (5)
Creatinine increase	2 (10)	0
Visual changes	2 (10)	0
Confusion	1 (5)	1 (5)
Headache	1 (5)	0

Toxicity	No. patients (%)	No. with dose-limiting toxicity (%)^*
Myelosuppression	19 (91)	1 (5)
Fatigue	11 (52)	3 (14)
Rash	7 (33)	0
Nausea	7 (33)	0
Bilirubin increase	5 (24)	0
Constipation	4 (19)	0
Diarrhea	3 (14)	0
Bone pain	3 (14)	0
Myalgia	2 (10)	1 (5)
Creatinine increase	2 (10)	0
Visual changes	2 (10)	0
Confusion	1 (5)	1 (5)
Headache	1 (5)	0

Twenty-one patients were evaluable for toxicity.

Dose-limiting toxicity was defined as grade 3 or 4 toxicity, except for hematologic toxicity, for which the criterion was grade 4 toxicity lasting more than 28 days after R115777 administration. Dose-limiting toxicity was assessed during the first 8 weeks of therapy.

View Large

This Feature Is Available To Subscribers Only